systemic hPBGD mRNA therapy (ModeRNA Therapeutics/University of Navarra)

N/A

Report date: 2025/03/20 14:52:36
NME

Base Information

Drug Namesystemic hPBGD mRNA therapy (ModeRNA Therapeutics/University of Navarra)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > OligonucleotideSmall molecules > Lipid
Mechanisms of ActionPorphobilinogen deaminase stimulants
TargetsPorphobilinogen deaminase
Therapy Area/IndicationsPorphyria, Acute Intermittent
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesModerna Inc
China Registration ClassN/A

Develop Information

Active CompaniesModerna IncUniversity Of Navarra
Inactive CompaniesN/A
Active IndicationsPorphyria, Acute Intermittent
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A